AMGN Stock News - Amgen Inc. Stock | Seeking Alpha

AMGN

Amgen Inc.NASDAQ

1d

5d

1m

6m

1y

5y

10y

Buy Or Sell Amgen? Why Not Do Both
Paul Franke • Fri, Dec. 23 • 13 Comments
Amgen declares $1.15 dividend
SA News • Tue, Dec. 20 • 27 Comments
Marketing application filed in Japan for osteoporosis candidate romosozumab
SA News • Tue, Dec. 20 • 2 Comments
Amgen, Regeneron May Yet Get Rich From Their Cholesterol Drugs
DoctoRx • Mon, Dec. 19 • 51 Comments
Amgen: More Willingness To Pay
Georgy Lazuk • Sun, Dec. 18 • 4 Comments
European Ad Comm backs once-monthly injection for Amgen's Repatha
SA News • Fri, Dec. 16 • 1 Comment
Stock Exchange: Do Emotions And Symbolism Affect Technical Analysis?
Jeff Miller • Fri, Dec. 16 • 6 Comments
Oppenheimer likes Amgen, sees 12% upside
SA News • Tue, Dec. 13 • 11 Comments
Spellman: Top dividend picks for 2017
Video at CNBC.com • Tue, Dec. 13
Amgen submits European marketing application for Avastin biosimilar
SA News • Fri, Dec. 2 • 3 Comments
Cytokinetics earns $26.7M milestone from Amgen on start of large-scale CV outcomes study of omecamtiv mecarbil
SA News • Thu, Dec. 1 • 5 Comments
Coherus Bio's marketing application for Neulasta biosimilar accepted for review
SA News • Wed, Nov. 30
Cramer Remix: why you shouldnt sell before year end
Video at CNBC.com • Tue, Nov. 29
Arrowhead to focus resources on subcutaneous and extra-hepatic RNAi therapeutics; three clinical-stage drug candidates axed; 30% of workforce cut; shares plummet 60% after hours
SA News • Tue, Nov. 29 • 43 Comments
Amgen: Enbrel Is Undervalued
Clinically Sound Investor • Mon, Nov. 28 • 6 Comments

From other sites

Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend

at TheStreet (Tue, 4:20PM)
Amgen Files for Approval of Osteoporosis Drug in Japan

at Zacks.com (Tue, 9:44AM)
Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan

at TheStreet (Mon, 7:00PM)
New Repatha® (evolocumab) Dose Delivery Option Receives Positive CHMP Opinion

at TheStreet (Dec 16, 2016)
Eyeing Amgen as a Low-Risk Buy

at TheStreet (Dec 13, 2016)
YieldBoost Amgen To 4.7% Using Options

at Nasdaq.com (Dec 12, 2016)
Amgen/Allergan File for EU Approval of Avastin Biosimilar

at Zacks.com (Dec 5, 2016)
Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

at TheStreet (Dec 2, 2016)
Amgen To Present At The Citi 2016 Global Healthcare Conference

at TheStreet (Dec 1, 2016)
Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016

at TheStreet (Nov 30, 2016)